These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 24039233)

  • 21. The ESA scenario gets complex: from biosimilar epoetins to activin traps.
    Jelkmann W
    Nephrol Dial Transplant; 2015 Apr; 30(4):553-9. PubMed ID: 24748667
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Erythropoietin in cancer patients: pros and cons.
    Dicato M; Plawny L
    Curr Opin Oncol; 2010 Jul; 22(4):307-11. PubMed ID: 20498598
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent advances in erythropoietic agents in renal anemia.
    Macdougall IC
    Semin Nephrol; 2006 Jul; 26(4):313-8. PubMed ID: 16949470
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessing erythropoiesis and the effect of erythropoietin therapy in renal disease by reticulocyte counting.
    Pradella M; Cavill I; d'Onofrio G
    Clin Lab Haematol; 1996 Dec; 18 Suppl 1():35-7. PubMed ID: 9054717
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Response to "Warning flags for erythropoiesis-stimulating agents and cancer-associated anemia".
    Littlewood TJ
    Oncologist; 2007 Aug; 12(8):1031-2; author reply 1032-4. PubMed ID: 17766663
    [No Abstract]   [Full Text] [Related]  

  • 26. The potential of erythropoietin and related strategies to stimulate erythropoiesis.
    Eckardt KU
    Curr Opin Investig Drugs; 2001 Aug; 2(8):1081-5. PubMed ID: 11892917
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of the pharmacist in optimizing the use of erythropoietin stimulating agents.
    Gebara SN; Moubayed H
    J Oncol Pharm Pract; 2010 Mar; 16(1):33-7. PubMed ID: 19401308
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer.
    Smith RE; Jaiyesimi IA; Meza LA; Tchekmedyian NS; Chan D; Griffith H; Brosman S; Bukowski R; Murdoch M; Rarick M; Saven A; Colowick AB; Fleishman A; Gayko U; Glaspy J
    Br J Cancer; 2001 Apr; 84 Suppl 1(Suppl 1):24-30. PubMed ID: 11308271
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Triumph and tragedy: anemia management in chronic kidney disease.
    Novak JE; Szczech LA
    Curr Opin Nephrol Hypertens; 2008 Nov; 17(6):580-8. PubMed ID: 18941350
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treating anemia associated with chronic renal failure with erythropoiesis stimulators: recombinant human erythropoietin might be the best among the available choices.
    Trkulja V
    Med Hypotheses; 2012 Jan; 78(1):157-61. PubMed ID: 22078846
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Retrospective observational study of patients with chemotherapy-related anemia receiving erythropoietic agents.
    Mark TL; McKenzie RS; Fastenau J; Piech CT
    Curr Med Res Opin; 2005 Sep; 21(9):1347-54. PubMed ID: 16197652
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New Treatment Approaches for the Anemia of CKD.
    Bonomini M; Del Vecchio L; Sirolli V; Locatelli F
    Am J Kidney Dis; 2016 Jan; 67(1):133-42. PubMed ID: 26372086
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The TREAT study answers a question, not the question.
    Coyne DW
    Am J Kidney Dis; 2008 Sep; 52(3):626-7; author reply 627-8. PubMed ID: 18725019
    [No Abstract]   [Full Text] [Related]  

  • 34. Renal anaemia and EPO hyporesponsiveness associated with vitamin D deficiency: the potential role of inflammation.
    Icardi A; Paoletti E; De Nicola L; Mazzaferro S; Russo R; Cozzolino M
    Nephrol Dial Transplant; 2013 Jul; 28(7):1672-9. PubMed ID: 23468534
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Response to "effect of patient exclusion criteria on the efficacy of erythropoiesis-stimulating agents in patients with cancer-related anemia".
    Coiffier B
    Oncologist; 2005 Oct; 10(9):762-3; author reply 764-5. PubMed ID: 16249359
    [No Abstract]   [Full Text] [Related]  

  • 36. How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: Adjuvant therapies to reduce erythropoiesis-stimulating agent dose requirements.
    Shah HH; Fishbane SN
    Semin Dial; 2013; 26(5):543-5. PubMed ID: 23763709
    [No Abstract]   [Full Text] [Related]  

  • 37. Cobalt chloride in the treatment of refractory anaemia in patients undergoing long-term haemodialysis.
    Bowie EA; Hurley PJ
    Aust N Z J Med; 1975 Aug; 5(4):306-14. PubMed ID: 810127
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Erythropoietin.
    Jelkmann W
    Front Horm Res; 2016; 47():115-27. PubMed ID: 27348128
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correcting anemia in heart failure: the efficacy and safety of erythropoiesis-stimulating agents.
    Lawler PR; Filion KB; Eisenberg MJ
    J Card Fail; 2010 Aug; 16(8):649-58. PubMed ID: 20670844
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of weekly darbepoetin alfa in the treatment of anaemia of HIV-infected haemodialysis patients.
    Lucas C; Carrera F; Jorge C; Boquinhas H; Pais MJ
    Nephrol Dial Transplant; 2006 Nov; 21(11):3202-6. PubMed ID: 16891651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.